Ipamorelin: the quietest growth hormone secretagogue

Most growth hormone peptides are sold on what they make go up. Ipamorelin is sold on what it doesn’t.

The pitch is the clean GHRP. Hits the same ghrelin receptor that older compounds like GHRP-6 or hexarelin hit, releases growth hormone the same way, but doesn’t drag cortisol or prolactin or ACTH up with it. That selectivity is the whole differentiator. In a category where the side effects are the part everyone quietly worries about, the compound that promises fewer of them sounds like the safe bet.

That story is real. The selectivity actually shows up in the animal work. The catch is that real in rats and useful in your body for the thing you’re hoping to use it for are two different sentences, and the gap between them has been honestly tested in humans exactly once.

Why ipamorelin keeps showing up

Ipamorelin was designed in the 1990s at Novo Nordisk to fix a known problem.

The earlier ghrelin-receptor agonists — GHRP-2, GHRP-6, hexarelin — pulled GH out of the pituitary effectively, but they were promiscuous. The same compound that triggered GH would also bump cortisol (a stress hormone) and prolactin (a lactation hormone) and ACTH (a pituitary signal to the adrenals). For a research compound aimed at GH biology, those extra effects were noise. For a hypothetical clinical drug, they were a deal-breaker.

The medicinal chemistry challenge was to find a ghrelin-receptor agonist that hit GH cleanly. Novo Nordisk got there with a synthetic pentapeptide — five non-natural amino acids in sequence (Aib-His-D-2-Nal-D-Phe-Lys) — that wasn’t a fragment of anything natural. It was designed to do one thing.

A 1998 paper in the European Journal of Endocrinology by Raun and colleagues introduced it as the first selective GH secretagogue and tested it in rat pituitary cell cultures and live rodents. Ipamorelin produced strong, dose-dependent GH release at potency comparable to GHRP-6 — the workhorse benchmark — while raising cortisol, prolactin, and ACTH far less. The selectivity story checked out in animals.

A 2000 follow-up in the Journal of Endocrinology by Svensson and colleagues looked at bone. Twelve weeks of ipamorelin in adult female rats raised bone mineral content and density at the lumbar vertebrae and femur versus controls, with no measured change in uterus or adrenal weight. The authors read that as favourable tissue selectivity. Still rats. Still preclinical. But suggestive of the same theme — ipamorelin doing the GH-mediated thing without pulling other endocrine levers.

That’s the mechanistic foundation the marketing rests on. Cleaner than older GHRPs, demonstrated in rodents, dose-proportional, selective. It’s a real chemistry story.

What the human PK looks like

A 1999 paper in Pharmaceutical Research by Gobburu and colleagues took ipamorelin into humans. Forty healthy male volunteers, five IV infusion rates, eight subjects per dose level. The trial was tightly designed for what it measured: pharmacokinetics, pharmacodynamics, and the shape of GH response.

The numbers were exactly what you’d expect from a well-behaved peptide. Dose-proportional PK. Terminal half-life around 2 hours. Clearance 0.078 L/h/kg. A single GH release event per dose, peaking at 0.67 hours and decaying exponentially. The researchers built a population PK/PD model that fit cleanly across doses.

What that trial did not measure is everything else. No efficacy endpoint. No clinical outcome. No body-composition tracking, no functional measurements, no patient-reported anything. It was a PK study and it produced PK answers. Ipamorelin moves through the body in a predictable way and releases GH on a predictable schedule. Confirmed. Whether moving through the body in a predictable way meant anything for an actual patient was a question for another trial.

So Raun, Svensson, and Gobburu are the rotation the marketing leans on: a selectivity story in rats, a bone signal in rats, and a pharmacokinetic profile in healthy adults. Coherent. Encouraging. Not actually evidence that the compound does anything clinically useful for a person.

The one human efficacy trial — and what it actually found

This is the section the marketing copy quietly skips, and it’s the load-bearing fact about ipamorelin’s clinical case.

In the late 2000s, Helsinn Healthcare took ipamorelin into a real Phase 2 program. The indication was postoperative ileus — the slow gut motility that follows abdominal surgery, which is a genuine clinical problem and a plausible target for a ghrelin-receptor agonist (ghrelin signalling promotes upper and lower GI motility). The trial was registered as NCT00672074, and it ran as a multicenter double-blind placebo-controlled study.

The results were published in 2014 in the International Journal of Colorectal Disease by Beck and colleagues — and the trial did not reach statistical significance on its primary endpoint. 117 patients enrolled. The intervention was intravenous ipamorelin twice daily for up to 7 days after bowel resection surgery, at the dose used by the Helsinn program. The key efficacy endpoint was median time from first dose to tolerance of a standardised solid meal.

Ipamorelin group: 25.3 hours. Placebo group: 32.6 hours. A 7.3-hour difference in the right direction, but the p-value was 0.15. The trial did not reach statistical significance on its primary endpoint. The published conclusion is explicit: no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses. Safety findings were unremarkable. Adverse event rates were comparable between arms.

The clean reading is: the trial was null. The 7.3-hour numerical difference looks suggestive, and somebody motivated could spin it as a trend toward efficacy. The p-value says no. Helsinn read the result the same way and discontinued the postoperative ileus development program. There has been no Phase 3 in any indication since.

That trial is the only registered controlled human evidence of ipamorelin doing anything clinically useful, and what it actually showed is that the compound did not meet its primary endpoint in the one indication a real sponsor was willing to take it through. Anyone citing ipamorelin’s human evidence without naming this trial and stating its result is selling something.

The stack marketing is the marketing

The most common consumer presentation of ipamorelin isn’t ipamorelin by itself — it’s ipamorelin paired with CJC-1295. The pitch is that CJC-1295 (the long-acting GHRH analog) raises the GH baseline while ipamorelin layers in pulsed bursts on top, and the combined effect is somehow more than either alone.

The mechanistic story has some basis. GHRH agonism and ghrelin-receptor agonism do hit different upstream levers on the pituitary, and there’s animal work showing additive or synergistic GH release when both are present. The 2026 Am J Sports Med primer by Mayfield and colleagues summarises the recent evidence: a CJC-1295 plus ipamorelin combination improved tetanic tension in a glucocorticoid-induced muscle loss mouse model. In mice with steroid-induced muscle wasting, the stack moved a muscle endpoint. Suggestive.

The same review names, in plain language, what’s missing: no human orthopaedic data supports the combination. The stack is in clinics, in compounding pharmacies, and in supplement marketing despite zero published controlled human trials of the specific pairing for any indication. The mouse-muscle finding is interesting. It is not evidence that someone in their forties stacking the two will end up with more muscle than a serious training programme alone.

The 2026 Frontiers in Aging review by Mavrych and colleagues reaches the same overall conclusion about the GH-modulation peptide cluster — mechanism is plausible, optimal dosing is not agreed, validated efficacy biomarkers don’t exist, and combination therapy effects are uncharacterised. That’s an honest read of the field by the field. It’s not the read that fits on a clinic landing page.

Where regulators sat — October 29, 2024

Ipamorelin has never been a marketed drug for any indication. The Helsinn POI program was the closest it ever got, and that ended at Phase 2.

It is not on the PCAC July 23–24, 2026 agenda — but the reason matters more than the absence does. The FDA already reviewed ipamorelin in 2024. After ipamorelin was removed from the Category 2 list in September 2024 and referred to PCAC, the committee evaluated it at the October 29, 2024 meeting and voted against inclusion on the 503A bulk drug substances list. The agency’s stated reasoning was the standard pattern: insufficient human safety data, mechanistic concerns, and a lack of reproducible efficacy data outside small or open-label trials. So the “not on the docket” framing flattens what actually happened. Ipamorelin isn’t on the July 2026 docket because PCAC already asked the question — eight months before the July meeting — and voted no.

WADA is straightforward. The S2 prohibited list covers peptide hormones, growth factors, related substances and mimetics. Ghrelin-receptor agonists fall inside that category by mechanism. Athletes subject to WADA testing should treat ipamorelin as banned in and out of competition, regardless of whether the literal compound name appears on the annual list.

What would settle the ipamorelin case

A controlled human trial in a healthy adult population — not surgical patients with ileus — measuring something the marketing actually promises. Body composition over a year, or sleep architecture with proper polysomnography, or functional fitness benchmarks. None of those have been run.

Independent replication of the Phase 1 PK signal in modern protocols, ideally subcutaneous rather than IV (since the consumer route is SC), and ideally over weeks rather than the single-dose escalation Gobburu measured.

A controlled human trial of the CJC-1295 plus ipamorelin combination, with a strength or recovery endpoint. The mouse muscle finding in Mayfield 2026 is worth following up. Following it up would mean actually testing the pairing in humans, which nobody has done.

A long-term safety dataset. The Gobburu 1999 acute pharmacology paper and the Beck 2014 7-day Phase 2 are the longest human exposures published. People prescribed ipamorelin for off-label longevity use often stay on it for months or years. That dataset doesn’t exist.

And a serious answer on why the Phase 2 program was abandoned, beyond the primary endpoint was null at p=0.15. Was the dose too low? Was the indication wrong? Did the combination with another agent get explored and shelved? Helsinn never publicly explained, and the institutional knowledge of why ipamorelin’s clinical development died at Phase 2 hasn’t been recovered.

Some of those answers could come if a current sponsor revived the development program. None of them are likely to come from compounding-pharmacy data, because compounding pharmacies don’t run controlled trials. The molecule lives on the lifestyle market for as long as people are willing to pay for cleaner ghrelin agonism on the basis of rat selectivity, predictable PK, and one null Phase 2 trial they were never told about.

What ipamorelin asks of you

The honest reason a lot of people walk away from ipamorelin isn’t the mechanism or the regulatory category. It’s the moment they read Beck 2014 in its own words and notice that nobody who sold them the compound mentioned the trial existed, let alone what it found. A clinician who skips the only Phase 2 in print is a clinician you’re paying to extrapolate around inconvenient evidence.

Wolverine Health is being built on the opposite principle. Physician-supervised peptide service, real prescriptions, US-licensed compounding pharmacies, every batch third-party tested — and the conversation about the evidence base includes the trials that didn’t go the way the marketing wants. We’re not selling you ahead of the science, and we’re not editing it for you either. Join the waitlist if you want a heads-up the moment that version is available.